CTCs Testing Services in Brain Tumors
Screening tumor cells from peripheral blood of tumor patients, and detecting and analyzing various vital information carried on them is a convenient, less invasive, and highly accurate method of detection. Circulating tumor cells (CTCs) are closely related to metastatic recurrence of cancer, and their presence may indicate metastasis of the tumor. CTCs, as one of the important markers of liquid biopsy, are important for early detection, efficacy assessment, and prognosis monitoring of metastatic brain tumors.
We offer testing services for CTCs in brain tumors
The amount of CTCs in the blood is very small, usually only 1-10 CTCs per ml of blood, and tens of billions of blood cells. Therefore, enrichment and screening of CTCs is a challenge in liquid biopsy. To address this problem, Alfa Cytology offers clients a variety of methods based on CTCs detection in brain tumors. This is the key to resolving the vital information carried by brain tumor CTCs.
The morphological method is based on isolation by the size of epithelial tumor cells (ISET)
CTCs can be detected by microscopy in peripheral blood. The ISET technique allows us to detect CTCs of various phenotypes in their entirety, reducing the impact of changes in surface marker expression during the epithelial-mesenchymal transition of tumor cells and improving the efficiency of CTCs and circulating tumor microemboli (CTM) detection. It also has the advantages of being rapid, convenient, and low cost, which is beneficial for subsequent experiments and studies.
In addition, we also provide single-cell sequencing services for CTCs in brain tumors. This can overcome the heterogeneity of CTCs, discover new driver genes in brain tumor development, and reveal the mechanisms of brain tumor metastasis, drug resistance, and recurrence. We can identify individual CTCs or CTM oncogenes and oncogenes, and analyze brain tumor survival factors.
Other brain tumors CTCs isolation and detection methods that we offer
| Category |
Methods |
Description |
| Isolation of CTCs |
Bioaffinity-based screening method |
We use the difference in expression of CTCs and blood cell surface biomarkers for isolation. This method does not encroach on the antigen binding sites on the surface of CTCs and does not require consideration of different cancer cell lines during isolation. |
| The physical property-based screening method |
CTCs differ significantly from blood cells in certain physical properties (e.g. size, shape, density, deformability, dielectric properties, adhesion). We offer several methods for the isolation of brain tumor CTCs based on these physical property differences, including membrane filtration methods, inertial focusing, deterministic lateral displacement (DLD), and dielectrophoresis (DEP). The method does not require immunostaining or antibody labeling of cells and does not consume expensive chemical reagents. The sample preparation time is shortened and the risk of cell damage is reduced. And secondly, it also enables high-throughput separation. |
| Detection of CTCs |
Fluorescence detection |
We use fluorescent antibodies to specifically react with brain tumor cells and observe the reacted cells under a fluorescence microscope to identify and localize CTCs. |
| Electrochemical detection |
We use electrodes to convert the concentration of the substance to be measured in the solution into an electrical signal for the detection of the component to be measured. This method has the advantages of rapid response, simpler experimental operation, and less impact on cell activity. |
| Surface-enhanced Raman scattering (SERS) detection |
We can detect brain tumor CTCs in peripheral blood with high sensitivity using precious metal SERS materials. |
As an important marker in liquid biopsy technology, CTCs can reflect the more complete biological information of brain tumors. Alfa Cytology provides the service of capturing and detecting brain tumor CTCs, which is very critical for real-time monitoring of brain tumor dynamics, assessing treatment efficacy, and personalizing treatment. Please contact our staff to learn how we analyze brain tumor CTCs.
All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.
